Advertisement

You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

December 5, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Prescription drug development costs skyrocket

The costs of developing new prescription drugs have soared 145% since 2003, according to a study from the Tufts Center for the Study of Drug Development (CSDD). » You won't believe the cost of developing a new prescription medicine

Express Scripts may switch hepatitis C drugs on preferred formulary

While pharmaceutical manufacturer AbbVie's new hepatitis C drug has not yet been approved by FDA, pharmacy benefits manager Express Scripts has expressed interest in switching to the drug in its preferred drug formulary. » Details here

Continuing Education

MTM essentials for weight management

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to educate pharmacists about the prevalence, health consequences, and nonpharmacologic and pharmacologic treatment options for obesity, with a focus on the recommendations made in the 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 14DT12-FKX42.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

FDA approves gel treatment for acne

FDA has approved 1.2% clindamycin phosphate and 3.75% benzoyl peroxide (Onexton Gel, Valeant Pharmaceuticals) for the once-daily treatment of comedonal and inflammatory acne in patients aged 12 and older. » Read more

 

RELATED ARTICLES

Skin cancer treatment costs soar

Drugs in Perspective: Sovaldi (sofosbuvir)

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group